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Signaling through RAS/MAP kinase pathway is cen-
tral to biology. ERK has long been perceived as
the only substrate for MEK. Here, we report that
HSF1, the master regulator of the proteotoxic stress
response, is a new MEK substrate. Beyond medi-
ating cell-environment interactions, the MEK-HSF1
regulation impacts malignancy. In tumor cells, MEK
blockade inactivates HSF1 and thereby provokes
proteomic chaos, presented as protein destabiliza-
tion, aggregation, and, strikingly, amyloidogenesis.
Unlike their non-transformed counterparts, tumor
cells are particularly susceptible to proteomic pertur-
bation and amyloid induction. Amyloidogenesis is
tumor suppressive, reducing in vivo melanoma
growth and contributing to the potent anti-neoplastic
effects of proteotoxic stressors. Our findings unveil a
key biological function of the oncogenic RAS-MEK
signaling in guarding proteostasis and suppressing
amyloidogenesis. Thus, proteomic instability is an
intrinsic feature of malignant state, and disrupting
the fragile tumor proteostasis to promote amyloido-
genesis may be a feasible therapeutic strategy.
INTRODUCTION
Following environmental challenges, cells stimulate production
of heat-shock proteins (HSPs). This HSP induction is the hall-
mark of the heat-shock, or proteotoxic stress, response (PSR)
(Lindquist, 1986). As molecular chaperones, HSPs facilitate
folding, transportation, and degradation of other proteins (Mori-
moto, 2008). In guarding the proteome against misfolding and
aggregation, the PSR preserves proteostasis (Balch et al., 2008).
In vertebrates, heat shock transcription factors (HSFs) govern
the PSR. Among them is HSF1, the master regulator of this
response (Morimoto, 2008; Xiao et al., 1999). As a multi-step
process, HSF1 activation entails trimerization, nuclear transloca-
tion, posttranslational modifications, and DNA binding (Mori-
moto, 2008). Yet, our understanding of this process remains
incomplete.
The HSF1-mediated PSR antagonizes many pathological
conditions, including hyperthermia, heavy-metal toxification,ischemia, and reperfusion, and oxidative damage, and impacts
aging and neurodegeneration (Dai et al., 2012a). HSF1, not sur-
prisingly, acts as a longevity factor (Hsu et al., 2003). In contrast,
our and others’ work has revealed a pro-oncogenic role of HSF1
(Dai et al., 2007, 2012b; Jin et al., 2011; Meng et al., 2010; Min
et al., 2007). Despite its dispensability under non-stress condi-
tions, HSF1 is crucial for tumor cells’ growth and survival (Dai
et al., 2007). Nonetheless, the mechanisms underlying its activa-
tion in malignancy remain unclear.
Here, we report that RAS-MEK-ERK signaling critically regu-
lates the PSR. It is MEK that phosphorylates and activates
HSF1. MEK inhibition destabilizes the proteome, provoking
protein aggregation and amyloidogenesis. Combinatorial pro-
teasome blockade potently augments this tumor-suppressive
amyloidogenic effect. Hence, our findings not only suggest
HSF1 as a new MEK substrate but also uncover a biological
function of RAS-MEK-ERK signaling in governing proteostasis.
Beyond shifting the canonical view of RAS-MEK-ERK signaling,
our proof-of-concept experiments suggest that intrinsic proteo-
mic instability associated with malignant state may be exploited
to combat cancer.
RESULTS
MEK and ERK Inversely Regulate the PSR
Phosphorylation notably impacts HSF1 activation (Guettouche
et al., 2005), suggesting a key role of signaling pathways.
To illuminate how such pathways regulate the PSR, we
first examined their responses to stress, focusing on RAS-
MEK-ERK signaling. To inflict proteotoxic stress, we applied
stressors with diverse mechanisms of action, including heat
shock (HS), proteasome inhibitor MG132, histone deacetylase
6 inhibitor tubastatin, amino-acid analog azetidine, and HSP in-
hibitors (17-DMAG for HSP90 and VER155008 for HSP70) (Ka-
waguchi et al., 2003; Massey et al., 2010; Morimoto, 2008;
Neckers and Workman, 2012). Transient exposure to stressors
did not impair cell viability (Figure S1A), but elevated phosphor-
ylation of MEK and ERK (Figure 1A), two key components of
this pathway. MEK Ser218/222 and ERK Thr202/Tyr204 phos-
phorylation signify their active state (Dhillon et al., 2007; Roux
and Blenis, 2004). Congruently, all stressors activated ELK1
(Figure 1B), a transcription factor downstream of ERK (Roux
and Blenis, 2004).
To determine whether MEK-ERK signaling regulates the
PSR, we employed U0126 and AZD6244, two specific MEK1/2Cell 160, 729–744, February 12, 2015 ª2015 Elsevier Inc. 729
Figure 1. MEK and ERK Oppositely Regu-
late the PSR
(A) NIH 3T3 cells were treated with HS at 43C for
30 min, 10 mM tubastatin A for 5 hr, 40 mM
VER155008 for 1 hr, 500 nM MG132 for 1 hr,
200 nM 17-DMAG for 1 hr, and 2.5 mM azetidine
for 15 min.
(B) The dual ELK1 reporter system, comprising a
serum response element (SRE)-driven secreted
embryonic alkaline phosphatase (SEAP) plasmid
and a CMV-driven Gaussia luciferase (GLuc)
plasmid, was transfected into HEK293T cells.
After 24 hr, cells were treated as in (A) and
recovered overnight before measuring reporter
activities (mean ± SD, n = 6, ANOVA).
(C and D) NIH 3T3 cells were treated with 20 mM
U0126 or 20 nM AZD6244 for 3 hr followed by HS
and 4 hr recovery. mRNA levels were quantitated
by qRT-PCR (mean ± SD, n = 3, Student’s t test).
(E) Immediately after HS, nuclear proteins of NIH
3T3 cells treated as in (C) were extracted to
measure HSF1-DNA binding by an ELISA-based
assay (mean ± SD, n = 3, ANOVA).
(F) HEK293T cells were transfected with dual
HSF1 reporter plasmids, a heat-shock element
(HSE)-driven SEAP plasmid and a CMV-GLuc
plasmid. After 24 hr, cells were treated with 20 mM
U0126, 20 nM AZD6244, 1 mM FR180204, or
100 nM Sch772984 for 3 hr followed by HS for
30 min and overnight recovery (mean ± SD, n = 6,
ANOVA).
(G) HEK293T cells were treated with different in-
hibitors overnight.
(H–K) A LacZ or MEK isoform plasmid was co-
transfected with dual HSF1 reporter plasmids into
HEK293T cells transduced with lentiviral small
hairpin RNAs (shRNAs). After 24 hr, cells were heat
shocked at 43C for 30 min followed by overnight
recovery (mean ± SD, n = 3, ANOVA).
(L–O) HEK293T cells were transfected with small
interfering RNAs (siRNAs) for 48 hr followed by
transfection with dual HSF1 reporter plasmids for
24 hr before HS (mean ± SD, n = 6, ANOVA).
See also Figure S1.
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inhibitors (Favata et al., 1998; Yeh et al., 2007). Both inhibitors
impeded the HS-induced transcription of Hsp genes and
impaired the DNA-binding capacity and transcriptional activa-
tion of HSF1 (Figures 1C–1F and S1B), suggesting that MEK ac-
tivates the HSF1-mediated PSR. ERK, phosphorylated by MEK
(Ahn et al., 1991), is widely recognized as the master effector
of this pathway (Dhillon et al., 2007; Roux and Blenis, 2004). Sur-
prisingly, ERK inhibitors, FR180204 and Sch772984 (Ohori et al.,
2005; Morris et al., 2013), activated HSF1 (Figures 1F and S1C).
Both MEK and ERK inhibitors impaired two ERK-mediated
events—MSK1 phosphorylation and ELK1 activation (Figures
1G and S1D) (Roux and Blenis, 2004). While MEK inhibitors
reduced ERK phosphorylation, two ERK inhibitors showed
distinct effects (Figure 1G). Sch772984 suppressed ERK phos-
phorylation, likely due to ERK conformational changes that block
MEK-mediated phosphorylation (Morris et al., 2013); conversely,
FR180204 promoted ERK phosphorylation (Figure 1G), suggest-
ing feedback MEK activation.
The impacts of MEK and ERK inhibitors on HSF1 were vali-
dated via genetic depletions of MEK and ERK (Figures 1I–1O).
While depletion of one ERK isoform diminished the other isoform
at the protein level (Figures 1L and 1N), mRNA levels of the iso-
form not targeted were elevated (Figures S1E–S1H), suggesting
posttranscriptional mechanisms underlying reduced proteins.
These results not only pinpoint RAS-MEK-ERK signaling as a
key regulator of the PSR, but also reveal divergent impacts of
MEK and ERK on HSF1.
MEK Physically Interacts with HSF1
To determine whether MEK directly activates HSF1, we exam-
ined endogenous MEK-HSF1 interactions by co-immunopre-
cipitation (coIP). While no evident MEK1/2 proteins were
precipitated with HSF1 without HS, HS caused a marked
coIP (Figures 2A and 2B), showing a stress-inducible MEK-
HSF1 interaction. The mobility shift of HSF1 marks HS-induced
phosphorylation (Figure 2A). These MEK-HSF1 interactions
were verified via expression of recombinant proteins (Figures
S2A and S2B). To determine whether MEK and HSF1 are in
direct contact, we employed the Proximity Ligation Assay
(PLA) technique (Clausson et al., 2011). Antibody specificities
were validated by immunostaining (Figures S2C and S2D).
In MEK-proficient cells, PLA signals were marginally visible
without HS and HS intensified these signals (Figure 2C). In
MEK-deficient cells, only faint signals were detected even after
HS (Figure 2C), confirming the specificity of PLA. Of note, PLA
signals were more manifest in the nucleus than in the cyto-
plasm (Figure 2C), revealing a prominently nuclear localization
of interactions. These results strongly suggest a direct MEK-
HSF1 association.
MEK1 and MEK2 form either homo- or heterodimers in vivo
(Catalanotti et al., 2009). To address which type of dimer binds
HSF1, we examined MEK1-HSF1 interactions in the deficiency
of MEK2. Under HS, more MEK1 proteins were precipitated
with HSF1 in MEK2-deficient cells (Figure 2D). Similarly, MEK1
deficiency heightened MEK2-HSF1 interactions (Figure 2E),
revealing a competition between the two MEK isoforms for
HSF1 binding and suggesting that MEK homodimers can
interact with HSF1.ERK Suppresses MEK-HSF1 Interactions
to Inactivate HSF1
To elucidate how ERK inactivates HSF1, we first examined the
impact of ERK on MEK-mediated HSF1 activation. Whereas
ERK1 depletion promoted MEK-HSF1 interactions (Figure 2F),
ERK1 overexpression mitigated these interactions and sup-
pressed HSF1 (Figures 2G and S2E). Thus, we contemplated
three possible scenarios (Figure 2H): (1) both MEK substrates,
ERK and HSF1, compete for MEK interaction; (2) ERK, like
MEK, binds HSF1 and thereby competes for HSF1 interaction;
and (3) ERK inhibits MEK kinase activity toward HSF1. Each of
the first two scenarios predicts competition between two protein
complexes; in contrast, the third scenario predicts that ERK as-
sembles withMEK andHSF1 into a single protein complex. Inter-
estingly, under HS HSF1 precipitated both MEK and ERK (Fig-
ure 2I), and ERK precipitated both MEK and HSF1 (Figure 2J).
Although these results do not exclude the existence of indepen-
dent MEK-ERK and MEK-HSF1 complexes, they argue against
the two complexes being stable and prevalent, as depicted in
the first scenario. To test the second scenario, we detected
ERK-HSF1 interactions by PLA, as this scenario predicts HSF1
as a substrate for both ERK and MEK. The specificity of ERK
antibodies was validated in ERK-depleted cells (Figure S2F). In
contrast to evident MEK1-ERK interactions (Figure 2K), no
apparent PLA signals denoting ERK-HSF1 interactions were
detected (Figure 2L), suggesting lack of direct contact between
these two proteins. Moreover, while ERK1 overexpression miti-
gated MEK-HSF1 interactions, less ERK1 proteins were precip-
itated with HSF1 (Figure 2G), conflicting with heightened ERK1-
HSF1 interactions predicted by the second scenario. Thus, these
results not only refute the second scenario but also suggest
that ERK complexes with HSF1 via MEK, in line with the third
scenario. Importantly, MEK depletion markedly diminished
ERK-HSF1 coIP (Figure 2J). These results suggest existence of
a protein complex comprising ERK, MEK, and HSF1, wherein
ERK suppresses HSF1 indirectly, via inhibition of MEK.
MEK Phosphorylates Ser326 to Activate HSF1
Under HS, HSF1 undergoes a series of phosphorylating events,
among which Ser326 phosphorylation stimulates its activation
(Guettouche et al., 2005). Yet, the identity of the kinase remains
elusive. To determine whether MEK phosphorylates Ser326, we
examined the effect of MEK blockade on this modification using
a phosphospecific antibody that recognized HSF1WT, but not
HSF1S326A, proteins (Figure S3A). Either MEK knockdown or
U0126 treatment impaired Ser326 phosphorylation (Figures 3A
and S3B). Conversely, a constitutively active mutant, MEK1DD
(S218D/S222D) (Brunet et al., 1994a), induced Ser326 phos-
phorylation and activation of HSF1 without HS (Figures 3B and
3C). ERK inhibition enhanced Ser326 phosphorylation, and
MEK depletion abolished this effect (Figures 3D and S3C), indi-
cating MEK-dependent regulation. HSF1S326A mutants dis-
played impaired transcriptional activities (Figure 3E), congruent
with their defective nuclear translocation and DNA-binding ca-
pacity (Figures S3D and 3F). Moreover, HSF1 proteins were
reduced in MEK-deficient cells (Figures 3A and S3E). To deter-
mine whether MEK impacts HSF1 stability, we performed
cycloheximide chase experiments. MEK depletion shortenedCell 160, 729–744, February 12, 2015 ª2015 Elsevier Inc. 731
Figure 2. ERK, MEK, and HSF1 Form a Stress-Inducible Protein Complex
(A and B) After HS at 43C for 30 min, endogenous HSF1 proteins were precipitated from HEK293T cells. WCL, whole cell lysate; HC, heavy chain.
(C) Endogenous MEK1-HSF1 interactions were detected by PLA in HeLa cells using a rabbit anti-MEK1 antibody and a mouse anti-HSF1 antibody. Scale bars
represent 50 mm for LM, 10 mm for HM.
(D and E) Endogenous MEK-HSF1 interactions were detected by IP in HEK293T cells stably expressing shRNAs.
(legend continued on next page)
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the half-life of HSF1WT protein; importantly, while HSF1S326A mu-
tants were less stable in MEK-proficient cells, their stability was
not evidently affected byMEK deficiency (Figure 3G), suggesting
that MEK stabilizes HSF1 largely via Ser326 phosphorylation.
These results indicate that MEK controls in vivo HSF1 Ser326
phosphorylation, a modification critical for its activation and
stability.
In vitro, recombinant MEK1 proteins directly phosphorylated
HSF1 at Ser326, and U0126 blocked this event (Figure 3H).
ERK was reported to phosphorylate HSF1 at Ser307 (Chu
et al., 1998), implying a direct ERK-HSF1 interaction. To exclude
direct Ser326 phosphorylation by ERK, we performed in vitro
HSF1 phosphorylation using immunoprecipitated endogenous
ERK complexes that would comprise ERK associated with or
without MEK. Although precipitated complexes phosphorylated
Ser326, this event was blocked by U0126, but not by FR180204
(Figure 3I). U0126, but not FR180204, blocked phosphorylation
of recombinant ERK1 proteins by the same precipitates (Fig-
ure 3I). In contrast, FR180204, but not U0126, blocked phos-
phorylation of myelin basic protein (MBP), a known ERK
substrate (Ahn et al., 1991), by the same precipitates (Fig-
ure 3I), showing ERK blockade by FR180204. These results
strongly suggest that MEK, rather than ERK, directly phosphor-
ylates Ser326. Moreover, recombinant ERK1 proteins impeded
in vitro HSF1 Ser326 phosphorylation by recombinant MEK1
proteins (Figure 3J), consistent with the suppression of Ser326
phosphorylation by ERK in vivo. In contrast, ERK promotes
HSF1 Ser307 phosphorylation. ERK depletion diminished
Ser307 phosphorylation, however, this effect was largely abol-
ished in MEK-deficient cells (Figure S3F), again indicating MEK
dependence. MEK inhibition impaired Ser326 phosphorylation
but enhanced Ser307 phosphorylation of HSF1WT proteins (Fig-
ure S3G). Interestingly, phosphomimetic mutant HSF1S326D pro-
teins displayed reduced basal Ser307 phosphorylation and
resisted induction of this phosphorylation byMEK inhibition (Fig-
ure S3G). These results support that Ser326 phosphorylation by
MEK represses Ser307 phosphorylation, and ERK impacts HSF1
Ser326 and Ser307 phosphorylation via MEK inhibition. Acti-
vated ERK phosphorylates Thr292/386 to inhibit MEK1 (Brunet
et al., 1994b). MEK1T292A,T386A mutants both heightened basal
HSF1 Ser326 phosphorylation and blocked ERK-mediated sup-
pression of this phosphorylation in cells depleted of endogenous
MEK (Figure 3K), indicating that ERK suppresses Ser326 phos-
phorylation via feedback phosphorylation of MEK.
Interestingly, two MEK1 mutations identified in human mela-
nomas, P124S and E203K (Nikolaev et al., 2012), caused consti-
tutive HSF1 phosphorylation and activation (Figures 3L and 3M).
Conversely, in human melanoma cells, MEK inhibitors impaired
constitutive HSF1 phosphorylation and binding to HSP pro-
moters (Figures 3N and 3O). These results indicate that MEK(F) Endogenous MEK-HSF1 interactions were detected in HEK293T cells transfe
(G) Endogenous HSF1-MEK and HSF1-GFP-ERK1 interactions were detected in
(H) Schematic depiction of three possible scenarios. P, phosphorylation.
(I) Immediately after HS, HSF1-ERK interactions were detected by coIP.
(J) Endogenous ERK-HSF1 interactions were detected in HEK293T cells stably e
(K and L) Endogenous ERK-MEK and ERK-HSF1 interactions were detected by
See also Figure S2.controls both inducible HSF1 activation in stressed cells and
constitutive HSF1 activation in malignant cells.
MEK Preserves Cellular Proteostasis
HSF1 could maintain cellular proteostasis via HSPs. To examine
the impacts of HSF1 on protein folding, we employed the gluco-
corticoid receptor (GR) as a model. Proper GR folding depends
on HSP90 and misfolded proteins are cleared by the ubiquitin-
proteasome system (Taipale et al., 2010). HSF1 knockdown
induced GR-GFP ubiquitination and depletion (Figure S4A), indi-
cating protein destabilization by HSF1 deficiency. This resulted
from diminished cellular chaperoning capacity, as lysates of
HSF1-deficient cells were less efficient in reactivating denatured
luciferase (Figure S4B). Similarly to HSF1 deficiency, MEK
blockade depleted GR-GFP, and this depletion is not due to
GFP instability or general expression changes, since co-ex-
pressed GFP was not affected (Figure 4A). Instead, MEK
blockade ubiquitinated GR-GFP (Figure 4B). This is not due to
impaired proteasomal function, as proteasome inhibition by Bor-
tezomib caused GR-GFP accumulation and MEK inhibitors did
not affect proteasomal activities (Figures S4C–S4E). In fact,
AZD6244 and MEK knockdown both depleted chaperoning
capacity (Figures 4C and S4F), revealing modulation of protein
folding and stability by MEK.
In line with a key role of HSF1 in governing cellular proteome,
HSF1 depletion induced protein Lys48-specific ubiquitination, a
modification marking proteins for proteasomal degradation
(Pickart and Eddins, 2004), in both detergent-soluble and -insol-
uble fractions (Figure S4G). This change suggests global protein
destabilization. Consistent with HSF1 inactivation, AZD6244
diminished Ser326 phosphorylation, reduced HSPs, and in-
duced overall ubiquitination (Figure 4D). Overnight AZD6244
treatment also destabilized HSF1 (Figures 4D and S4H). MEK
knockdown induced global ubiquitination as well (Figure S4I).
Importantly, AZD6244 failed to deplete HSF1 and provoke ubiq-
uitination in cells stably overexpressing HSF1S326D (Figures 4E
and S4J), indicating a causative role of HSF1 inactivation in pro-
tein instability due to MEK inhibition. In vivo MEK inhibition also
depleted HSPs andHSF1 and provoked ubiquitination in primary
tissues (Figure 4F).
To investigate ubiquitomic changes due to MEK inhibition, we
conducted mass spectrometry (MS)-based analyses of ubiquiti-
nated peptides enriched by a novel ubiquitin branch motif
antibody (Figure 4G) (Kim et al., 2011). We compared the ubiqui-
tomes of A2058 cells treated with and without AZD6244 for 8 hr.
In total, 3,425 non-redundant ubiquitinated peptides, assigned
to 1,715 distinctive proteins, were profiled (Figures 4H and
S4K; Table S1). AZD6244 both increased and decreased peptide
ubiquitination (Figure 4H). When a 2.5-fold cutoff was defined
as the significant change, a collection of 76 non-redundantcted with siRNAs.
HEK293T cells transfected with indicated plasmids.
xpressing shRNAs.
PLA in HeLa cells. Scale bars represent 50 mm for LM, 10 mm HM.
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Figure 3. MEK Phosphorylates Ser326 to Activate HSF1
(A and B) HSF1 Ser326 phosphorylation was measured by immunoblotting in HEK293T cells stably expressing shRNAs or transfected with MEK1DD plasmid.
(C) GFP or MEK1DD plasmids were co-transfected with dual HSF1 reporter plasmids into HEK293T cells (mean ± SD, n = 5, Student’s t test).
(D) Control or ERK-targeting siRNAs, A (siERK1_1 and siERK2_1) and B (siERK1_3 and siERK2_2), were transfected into HEK293T cells stably expressing
shRNAs.
(E) GFP or FLAG-HSF1 plasmids were co-transfected with dual HSF1 reporter plasmids into HEK293T cells stably expressing shRNAs (mean ± SD, n = 6,
ANOVA).
(legend continued on next page)
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peptides were distinguished. These peptides represent 68
unique proteins that perform diverse molecular functions and
engage in a wide array of biological processes (Figures 4I and
4J). Intriguingly, the most enriched pathway was translation
elongation (Figure 4J). Analyses of these 68 proteins revealed
a functional association network encompassing three sub-
networks (Figure 4K). Of particular interest is the ‘‘translation’’
subnetwork that consists of 7 ribosomal subunit proteins, high-
lighting a prominent impact of MEK on ribosome machinery.
Moreover, embedded within the network are several oncogenes
and tumor suppressors, including c-MYC, Cyclin D1, HIF1A,
TP53, and NF1 (Figure 4K). Although the mechanisms whereby
MEK regulates these key players in oncogenesis are likely multi-
faceted, accumulating evidence has implicated HSPs in modu-
lating their stabilities (Isaacs et al., 2002; Mu¨ller et al., 2004).
Thus, MEK could impact these proteins at least in part via HSF1.
To validate our MS findings, we elected several target pro-
teins. Torsin-1A interacting protein 2 (TOR1AIP2) and ribosomal
protein L3 (RPL3) exhibited 61.0- and 13.7-fold increases,
respectively, in ubiquitination (Table S1). To facilitate detection,
we expressed V5-tagged TOR1AIP2 and RPL3 proteins via a
constitutive promoter. AZD6244 treatment for 8 hr did not alter
levels of both V5-tagged proteins but increased their ubiqui-
tination (Figures 4L and 4M). Our MS results also revealed
decreased ubiquitination of proteins including c-MYC, RPL15,
RPL24, and RPS20 (Table S1). We confirmed reductions in
both ubiquitination and total levels of endogenous c-MYC
proteins (Figure 4N). Similar results were also observed for V5-
tagged RPL15, RPL24, and RPS20 (Figures S4L–S4N), suggest-
ing shortened protein half-life. Indeed, proteasome blockade by
MG132 prevented RPL15-V5 depletion by AZD6244 and re-
vealed its elevated ubiquitination (Figure 4O). Consistent with a
critical role of HSF1 inactivation, both V5-tagged RPL15 and
RPL3 proteins were highly ubiquitinated following HSF1 knock-
down, and AZD6244 subtly affected this ubiquitination (Figures
4O and 4P). Importantly, MG132 prevented depletions of endog-
enous RPL15 and RPL3 by AZD6244 and MEK knockdown
(Figures 4Q and S4O), confirming destabilization of ribosomal
proteins by MEK deficiency. While HSF1 knockdown diminished
endogenous RPL15 and RPL3, HSF1S326D expression elevated
their basal levels and protected them from AZD6244-induced
depletions (Figures 4R and S4P). These findings together indi-
cate that MEK inhibition inactivates HSF1 to deplete cellular(F) FLAG-HSF1 plasmids were transfected into HEK293T cells stably express
described in Figure 1E using anti-FLAG antibodies. The results were normalized
(G) FLAG-HSF1 proteins were detected in HEK293T cells treated with 20 mg/ml
(H) Purified GST-MEK1 proteins (100 ng) were incubated with U0126 at RT for 2
30 min. HSF1 phosphorylation was detected by immunoblotting.
(I) ERK complexes precipitated from HEK293T cells were treated with U0126 or F
1,000 ng MBP proteins.
(J) Inactive GST-ERK1 proteins were incubated with 100 ng GST-MEK1 and 400
(K) LacZ or GFP-ERK1 plasmid was co-transfected with MEK1WT or MEK1T292A,
(L) HSF1 Ser326 phosphorylation was detected in HEK293T cells transfected wi
(M) HSF1 activities were measured by the dual reporter system in HEK293T cells
(N) WM115 cells were treated with 20 nM AZD6244 or 20 mM U0126 overnight.
(O) HSF1 chromatin immunoprecipitation (ChIP) assays were performed using W
normalized against the values of IgG controls (mean ± SD, n = 3, ANOVA).
See also Figure S3.chaperoning capacity. In consequence, protein destabilization
and ubiquitomic imbalance ensue.
MEK Inhibition Provokes Aggregation and
Amyloidogenesis in Malignant Cells
Increased ubiquitination in detergent-insoluble fractions sug-
gests protein aggregation (Figure 4D). To demonstrate this,
we performed ubiquitin immunostaining. Melanoma cells were
treated with Bortezomib and AZD6244 for 24 hr to provoke
evident aggregation. As expected, bright fluorescent punctate
foci emerged in Bortezomib-treated cells (Figure 5A), demar-
cating ubiquitin-containing aggregates. AZD6244 depleted
HSF1 and, albeit to a lesser extent, induced punctate foci
(Figures 5A and S5A). We theorized that blockade of protea-
somal degradation of AZD6244-induced misfolded proteins
would aggravate aggregation. Indeed, Bortezomib co-treatment
augmented AZD6244-induced punctate foci (Figure 5A). We
further confirmed the impact of MEK on aggregation using an
expanded polyglutamine tract protein (polyQ79) (Sa´nchez
et al., 2003). Proteins with expanded polyQ fragments are
aggregation-prone and causally related to neurodegenerative
disorders (Orr and Zoghbi, 2007). PolyQ79-expressing cells, as
expected, contained large aggregates (Figure S5B). HSF1
knockdown and AZD6244 both enlarged polyQ aggregates;
importantly, HSF1S326D expression antagonized AZD6244-
induced aggregate enlargement (Figures 5B and S5C). Bortezo-
mib also enhanced aggregation, and combined treatment
produced the largest aggregates (Figure 5B). Thus, both MEK
and the proteasome suppress protein aggregation.
Aggregation-prone proteins can form amyloid fibrils (AFs)
enriched for b sheet structures (Eisenberg and Jucker, 2012).
To assess whether HSF1 and MEK impact amyloid formation,
we stained polyQ79-expressing cells with Thioflavin T (ThT)
and Congo red (CR), two fluorescent dyes widely used to diag-
nose amyloids (Chiti and Dobson, 2006). PolyQ79 expression
enhanced ThT and CR staining (Figures S5D and S5E), as ex-
pected. AZD6244, Bortezomib, and combined treatment further
intensified this staining, and HSF1S326D expression antagonized
the effect of AZD6244 (Figure 5C). Treatments also enhanced
ThT and CR staining of human tumor cell lines (Figures 5D
and S5F), suggesting emergence of endogenous amyloid-like
structures. The presence of soluble amyloid oligomers (AOs)
confirmed amyloidogenesis. AOs are believed to constitute aing HSF1-targeting shRNAs. HSF1-DNA binding was measured after HS as
against nuclear FLAG-HSF1 levels (mean ± SD, n = 3, Student’s t test).
cycloheximide (CHX). Co-expressed GFP proteins served as internal controls.
0 min followed by incubation with 400 ng purified His-HSF1 proteins at RT for
R180204, followed by incubation with 400 ng His-HSF1, 400 ng GST-ERK1, or
ng His-HSF1 proteins at RT for 30 min.
T386A plasmid into HEK293T cells stably expressing MEK-targeting shRNAs.
th indicated plasmids.
transfected with indicated plasmids (mean ± SD, n = 6, ANOVA).
M115 cells treated with DMSO or 20 nM AZD6244 overnight. The results were
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Figure 4. MEK Preserves Proteostasis
(A) GFP and GR-GFP plasmids were co-trans-
fected into HEK293T cells followed by treatments
with 20 nM AZD6244, 20 mM U0126, or 200 nM
17-DMAG for 4 hr.
(B) GR-GFP plasmids were co-transfected into
HEK293T cells with HA-Ub-K48 plasmids, which
encode a mutant ubiquitin that can be conjugated
to protein substrates only via lysine 48. Following
treatments with 20 nM AZD6244 or 200 nM
17-DMAG for 4 hr, GR-GFP proteins were
precipitated and ubiquitination was detected us-
ing anti-HA antibodies.
(C) Denatured firefly luciferases were incubated
with lysates of A2058 cells treated with DMSO or
20 nM AZD6244 (mean ± SD, n = 4, ANOVA).
(D) A2058 cells were treated with 20 nM AZD6244,
and ubiquitinated proteins were detected in both
detergent-soluble and detergent-insoluble frac-
tions using Lys48-specific ubiquitin antibodies.
(E)A2058cells stablyexpressingLacZorHSF1S326D
were treated with 20 nM AZD6244 for 8 hr.
(F) C57BL/6J mice were i.p. injected with DMSO
or AZD6244 three times a week for 2 weeks. S,
spleen; K, kidney; L, liver.
(G) Experimental procedures of MS-based quan-
titation of ubiquitinated peptides, two technical
replicates per treatment.
(H) Scatter plot of relative changes in peptide
abundancebetween treated andcontrol conditions.
The green and red lines indicate 2.5-fold cutoffs.
(I) The classification of the 68 proteins was per-
formed using the PANTHER gene list analysis tool
(http://www.pantherdb.org).
(J) The Gene Ontology (GO) biological process
enrichment analysis was performed using the
web-based Enrichr software application.
(K) Interaction network of the 68 proteins. Known
and predicted protein interactions were derived
from the STRING database (http://www.string-db.
org), and the network was visualized using Cyto-
scape software.
(L and M) TOR1AIP2-V5 or RPL3-V5 plasmids
were co-transfected with HA-Ub-K48 plasmids
into HEK293T cells. Following 20 nM AZD6244
treatment for 8 hr, proteins were precipitated with
anti-V5 antibodies.
(N) Following AZD6244 treatment, endogenous c-
MYC proteins were precipitated from A2058 cells
and immunoblotted with anti-ubiquitin antibodies.
(O and P) RPL15-V5 and RPL3-V5 plasmids were
co-transfected with HA-Ub-K48 plasmids into
HEK293T cells stably expressing shRNAs. Cells
were treated with 500 nM MG132 alone or co-
treated with 20 nM AZD6244 for 8 hr.
(Q) Endogenous RPL15 and RPL3 proteins were
detected in A2058 cells treated with 20 nM
AZD6244 alone or co-treated with 500 nMMG132.
(R) Endogenous RPL15 and RPL3 proteins were
detected in A2058 cells stably expressing LacZ or
HSF1S326D with AZD6244 treatment.
See also Figure S4 and Table S1.key toxic species in neurodegenerative disorders and can be
detected by the conformation-dependent antibody A11 (Chiti
and Dobson, 2006; Glabe, 2008; Kayed et al., 2003). Treatments736 Cell 160, 729–744, February 12, 2015 ª2015 Elsevier Inc.not only exaggerated AO induction by polyQ79, but also pro-
voked genesis of endogenous AOs in human tumor cell lines
(Figures 5E and 5F). Similarly to AZD6244, HSF1 depletion
induced endogenous AOs and AFs (Figures S5G and S5H). A
previously characterized antibody, OC, was used to detect AFs
(Kayed et al., 2007). Again, HSF1S326D expression suppressed
AZD6244-induced amyloidogenesis (Figures 5G and 5H).
A unique feature of amyloids is their ability to seed AFs (Chiti
and Dobson, 2006). In amyloid seeding experiments, lysates
of HSF1-depleted cells accelerated formation of Ab AFs
(Figure S5I). Similarly, lysates of cells treated with AZD6244, Bor-
tezomib, and combination all exhibited augmented seeding
efficacy (Figure 5I), which was confirmed using OC antibodies
(Figure S5J). HSF1S326D expression abolished the effect of
AZD6244 (Figure 5I). Furthermore, transmission electron micro-
scopy revealed that while seeding with DMSO-treated cell
lysates resulted into disordered rod-like protofibrils, a dense lat-
tice of fiber-like structures emerged following seeding with
AZD6244-treated lysates; in comparison, seeding with Bortezo-
mib-treated lysates produced mature fibrils, and a compacted
network of fibrils were assembled after seeding with lysates
from combined treatment (Figure 5J).
The amyloidogenic effects of AZD6244 and Bortezomib were
validated genetically. Depletion of the b5 subunit (PSMB5) of
the 26S proteasome, a primary target of Bortezomib (Oerlemans
et al., 2008), caused accumulation of ubiquitinated proteins (Fig-
ure S5K). Mimicking pharmacological inhibitors, genetic deple-
tions of MEK, PSMB5, or both all provoked amyloidogenesis
(Figures 5K and S5L–S5Q).
To determine whether amyloids contribute to inhibitor-
induced toxicities, we blocked amyloidogenesis with ThT, which
impedes amyloid fibrillization via physical binding (Alavez et al.,
2011). In melanoma cells, ThT suppressed amyloid induction
by inhibitors and improved cellular growth and survival by 50%
(Figures 5L–5N). CR treatment and neutralization of AOs with
A11 antibodies exerted similar protection (Figures 5O and
S5R). Congruent with mitigated amyloidogenesis, HSF1S326D
expression not only stimulated the growth of melanoma cells
but also rendered them refractory to MEK inhibition (Figure 5P).
Surprisingly, AZD6244 did not induce AOs in primary mouse
embryonic fibroblasts (MEFs) and tissues (Figures 5Q and S5S).
This is not due to inability to detect murine amyloids, as severe
stress did induce AOs in murine cells (Figure S5T). These results
suggest that non-transformed cells may be more refractory to
amyloidogenesis than malignant cells. To assess this, we
compared AO levels in primary human mammary epithelial cells
(PHMC), immortalizedhumanmammaryepithelial (MCF10A) cells,
and tumorigenic mammary epithelial (MCF7) cells treated with
AZD6244, Bortezomib, and the combination. Each of these three
treatments caused marked AO induction in MCF7 cells, slight in-
duction in MCF10A cells, and no induction in PHMC (Figure 5R).
A similar pattern was observed in primary human Schwann cells
(PHSC) and their malignant counterparts, 90-8TL and S462 cells
(Figure 5S). Immortalized and transformed cells, except S462,
also showed elevated basal levels of AOs (Figures 5R and 5S).
Intriguingly, AO levels positively correlated with malignant states
(Figure5T), supportingproteomic imbalance asan intrinsic feature
ofmalignancy.We theorized that the lack of elevated basal AOs in
S462 cells might be due to amyloid-associated toxicity. Indeed,
blockade of cell death by a pan-caspase inhibitor (CI) elevated
AO levels in immortalized and transformed cells, revealing height-ened amyloidogenesis; in contrast, it did not elevate AOs in pri-
mary cells (Figures 5T and 5U), supporting an absence of amyloi-
dogenesis. These results indicate that malignant cells are
distinctively susceptible to amyloidogenesis.
Combined Proteasome and MEK Inhibition Disrupts
Tumor Proteostasis and Suppresses Malignancy
MEK and proteasome inhibition, individually, disturbed proteo-
stasis in tumor cells to certain degrees, however, the combina-
tion of both augmented this effect and, accordingly, markedly
impaired the growth and survival of human tumor cell lines (Fig-
ure 6A). Of note, this combination did not impact primary cells
(Figure 6A).
In vivo, whereas low doses of AZD6244 or Bortezomib alone
exhibited no significant impacts on xenografted melanomas,
the combination potently retarded their growth (Figures 6B and
S6A). All mice receiving the combined treatment remained alive
and their bodyweights remained constant; in contrast, all mice in
the other groups died and lost25% of body weight (Figures 6C
and S6B). AZD6244 or Bortezomib alone slightly elevated ubiq-
uitination in tumors, however, the combination markedly aggra-
vated this effect (Figures 6D and S6C). While Bortezomib
induced HSF1 Ser326 phosphorylation and HSP expression,
AZD6244 co-treatment suppressed this stress response and
induced caspase 3 cleavage (Figures 6D and S6C). Accordingly,
AOswere evidently elevated in tumors receiving combined treat-
ment (Figure 6E). Of particular interest is an inverse correlation
between amounts of AOs and tumor masses (Figure S6D), sup-
porting an adverse impact of AOs on malignant growth.
Congruent with amyloidogenesis, tumors receiving combined
treatment displayed potent seeding capacities and enhance-
ment of CR staining (Figures 6F and 6G). Intratumoral AFs
were further demonstrated by the hallmark birefringence of CR
staining (Figure 6H), ThT labeling (Figure S6E), and immunostain-
ing with OC antibodies (Figure 6I). In contrast, the combined
treatment did not induce AOs and apoptosis in primary tissues
of the same tumor-bearing mice, despite elevated ubiquitination
(Figures S6F and S6G).
To investigate whether the combined treatment impedes
experimental metastasis, we intravenously injected melanoma
cells expressing a luciferase transgene into NOD/SCID mice.
During a 6-week period, onlymice receiving combined treatment
gained body weight (Figure 6J), suggesting improved health.
In vivo imaging detected luminescence in 40% of mice treated
with DMSO, AZD6244, or Bortezomib alone (Figure 6K). Histo-
logical examination confirmed melanoma metastases to the
lung, skeletal muscle, adipose tissue, and ovary (Figure 6L; Table
S2). In contrast, none of the mice receiving combined treatment
displayed discernible luminescence or metastases (Figures 6K
and 6M). Together, these results demonstrate that combined
MEK and proteasome inhibition provokes proteotoxic stress
and amyloidogenesis within tumors and exerts robust anti-
neoplastic effects.
Amyloidogenesis Is Tumor Suppressive
Evident apoptosis in tumor regions showing intense CR
staining suggests a causative role of amyloidogenesis in treat-
ment-induced toxicity (Figure 7A). To confirm this, we blockedCell 160, 729–744, February 12, 2015 ª2015 Elsevier Inc. 737
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intratumoral amyloid induction via in vivo CR administration. CR
not only accelerated melanoma growth but also potently antag-
onized the tumor suppression imposed by combined MEK and
proteasome inhibition (Figure 7B). Penetration of CR into tumor
tissues was indicated by intense light absorption of tumor ly-
sates at 498 nm (Figure 7C), a characteristic of this amyloid stain
(Sladewski et al., 2006). Congruent with enhanced malignancy,
CR treatment enlarged tumor masses, deteriorated body condi-
tions, and shortened animal survival (Figures 7D, S7A, and S7B).
While CR reduced amyloids in tumor tissues, it did not
diminish ubiquitination (Figures 7E–7G). These results indicate
no interference of CR with MEK and proteasome inhibitors and
further support a specific action of CR in blocking amyloid gen-
esis. In accordance with accelerated growth, CR-treated tumors
displayed reduced caspase 3 cleavage (Figure 7G). Collectively,
these results strongly suggest that amyloidogenesis is tumor
suppressive and evidently contributes to the anti-neoplastic ef-
fects of combined MEK and proteasome inhibition.
DISCUSSION
HSF1 Is a New MEK Substrate
Unexpectedly, our results reveal HSF1 as a physiological sub-
strate for MEK, challenging the prevailing paradigm wherein
ERK exclusively instigates the effects of RAS-RAF-MEK
signaling. Our results further show that MEK activates but ERK
inactivates HSF1. Importantly, our findings integrate these two
seemingly contradictory actions and support the assembly of a
ternary ERK-MEK-HSF1 protein complex. In aggregate, our find-
ings propose a bifurcated, rather than a linear, RAS-RAF-MEK
cascade. MEK, as a central nexus, both conveys upstream stim-
uli and governs two discrete but interconnected downstream
effector pathways, of which one is mediated by ERK and the
other by HSF1 (Figure 7H). In a negative feedback fashion,Figure 5. MEK and Proteasome Inhibition Provoke Protein Aggregatio
(A) WM115 cells treated with 20 nM AZD6244, 100 nM Bortezomib, or both for 2
ubiquitin-positive aggregates. Scale bar represents 10 mm. Amounts of aggrega
(B and C) Following transfection with polyQ79 plasmids alone or with both poly
inhibitors as described in (A). Cells were either analyzed for aggregate size or sta
(D) Treated tumor cell lines were stained with 10 mM ThT. Geometric means were
values were presented as a heat map.
(E) HEK293T cells were transfected with LacZ or polyQ79 plasmid. Following treat
ANOVA).
(F) Intrinsic AOs were detected in human tumor cell lines (mean ± SD, n = 3, ANO
(G and H) A2058 cells stably expressing LacZ or HSF1S326D were treated for 24
(I) Synthetic Ab1-42 peptides (20 mM) were incubated at RT with gentle shakin
monitored by ThT binding (mean ± SD, n = 3, ANOVA).
(J) For TEM studies (left panel, 80,0003; right panel, 200,0003), 20 mM synthetic
gentle shaking for 2 days. Scale bars represent 100 nm.
(K) HEK293T cells stably expressing different shRNAs were stained with 10 mM T
(L and M) After pre-incubation with 10 mM ThT for 6 hr, A2058 cells were treated
(N and O) After pre-incubation with 10 mM ThT for 6 hr or transfection with 100 ng
24 hr. Viable cells were quantitated using CellTiter-Blue reagents (mean ± SD, n
(P) A2058 cells stably expressing LacZ or HSF1S326D were treated with DMSO o
Relative changes in viable cells after treatment were calculated by normalizing th
each time point.
(Q–S) Following treatments with 20 nMAZD6244, 100 nMBortezomib, or both for 2
ANOVA).
(T and U) Cells were treated with 50 mM Q-VD-OPh overnight and AOs were qua
See also Figure S5.ERK finely attunes HSF1 activation via inhibitory phosphorylation
of MEK (Figure 7H). While our studies focused onMEK-mediated
Ser326 phosphorylation, other kinases can also regulate HSF1.
Guarding of Proteostasis by RAS-RAF-MEK Signaling
Our findings uncover a new function of RAS-RAF-MEK sig-
naling in regulating proteostasis. Diverse proteotoxic stressors
commonly activate MEK (Figure 1A). Through HSF1 activation,
RAS-RAF-MEK signaling heightens cellular chaperoning capac-
ity to guard proteomic integrity.
MEK-HSF1 regulation could have key physiological implica-
tions. Mitogens stimulate RAS/MAPK signaling and downstream
mTORC1 (Laplante and Sabatini, 2012). However, heightened
protein synthesis driven by mTORC1 encumbers cellular protein
quality-control machinery. It thus appears necessary for mito-
gens, via MEK, to concurrently mobilize the HSF1-controled
chaperone system to ensure productive protein synthesis and,
thereby, avert proteomic imbalance. Interestingly, MEK also
governs translation capacity via HSF1 (Figure 4K). Thus, RAS-
RAF-MEK signaling synchronizes protein quantity- and quality-
control machineries to support cellular growth.
It is also tempting to speculate that RAS-RAF-MEK signaling
may antagonize protein-misfolding diseases, such as amyloid-
osis, via guarding proteostasis.
Proteomic Instability of Cancer
Our findings pinpoint a pro-amyloidogenic nature of malignant
state. The susceptibility of malignant cells to amyloid genesis
likely originates from their debilitated proteostatic state, which
is particularly vulnerable to perturbations. Unlike non-trans-
formed cells, malignant cells constantly endure proteomic imbal-
ance, evidenced by elevated basal levels of amyloids (Figures 5T
and 5U). Accordingly, HSF1, otherwise latent in primary cells,
is constitutively mobilized in tumor cells to retain the fragilen and Amyloidogenesis
4 hr were stained with Lys48-specific ubiquitin antibodies. Arrowheads mark
tes per cell were quantitated using ImageJ (median, nR 100, ANOVA).
Q79 and HSF1S326D plasmids for one day, HEK293T cells were treated with
ined with 10 mM ThT.
used to calculate fold changes in ThT fluorescence intensity and the log2(FC)
ments, AOs were quantitated by ELISA using A11 antibodies (mean ±SD, n = 3,
VA).
hr. Amyloids were quantitated by ELISA (mean ± SD, n = 3, Student’s t test).
g with 20 mg lysates of A2058 cells treated with inhibitors. AF formation was
Ab1-42 peptides were incubated with A2058 cell lysates in PBS at 37C with
hT.
for 24 hr. Amyloids were quantitated (mean ± SD, n = 3, Student’s t test).
A11 antibodies using JBS-Proteoducin for 16 hr, A2058 cells were treated for
= 6, Student’s t test).
r 20 nM AZD6244. Viable cells were quantitated (mean ± SD, n = 6, ANOVA).
e values of AZD6244-treated cells against the values of DMSO-treated cells at
4 hr, AOswere quantitated in primaryMEFs and human cells (mean ±SD, n = 3,
ntitated (mean ± SD, n = 3, Student’s t test).
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proteomic equilibrium (Figure 7H). Proteomic chaos inevitably
ensues following either HSF1 inactivation or even mild pro-
teotoxic insults. Hence, tumors cells rely on HSF1 to sustain
their malignant phenotypes (Dai et al., 2007). In contrast,
the lack of intrinsic proteotoxic stress empowers primary
cells to effectively buffer intense proteomic fluctuations and
thereby avert deleterious consequences—aggregation and
amyloidogenesis.
Excitingly, the distinct susceptibilities to proteomic perturba-
tion between primary and malignant cells may be exploited to
combat malignancy. Our findings support important roles for
proteotoxic stress and amyloidogenesis in the toxicity of MEK
inhibition in malignancy. Through protein destabilization, MEK
inhibitors act as a proteotoxic stressor, mechanistically distinct
from proteasome inhibitors. When applied as single agent,
a MEK or proteasome inhibitor is incompetent to distress
tumor proteostasis. However, combinatorial application exerts
a profound impact, eliciting amyloidogenesis. Importantly, our
findings strongly suggest a tumor-suppressive nature of amyloi-
dogenesis (Figures 5L–5O and 7B). These findings imply that
amyloidogenesis, indicative of grave proteomic imbalance,
may be of prognostic value in monitoring tumor progression
and evaluating therapeutic responses. Conceptually, our find-
ings suggest that proteomic instability is an intrinsic character-
istic associated with malignant state and that, therefore, disrup-
tion of fragile tumor proteostasis may be a feasible therapeutic
strategy.
EXPERIMENTAL PROCEDURES
Proximity Ligation Assay
Cells were fixed with 4% formaldehyde in PBS for 15 min at room temperature
(RT). After blocking with 5% goat serum in PBS with 0.3% Triton X-100, cells
were incubated with a pair of rabbit and mouse primary antibodies 1:200
diluted in the blocking buffer overnight at 4C. Following incubation with Duo-
link PLA anti-rabbit Plus and anti-mouse Minus probes (OLINK Bioscience) at
37C for 1 hr, ligation, rolling circle amplification, and detection were per-
formed using Duolink In Situ Detection Reagents Red (OLINK Bioscience).
Nuclei were stained with Hoechst 33342. Signals were visualized using a Leica
TCS SP5 confocal microscope.Figure 6. Combined MEK and Proteasome Inhibition Exerts Potent Tu
(A) After treatmentswith 20nMAZD6244, 100 nMBortezomib, or both for 24hr, viabl
(B and C) A2058 cells (13 106) were s.c. injected into NOD/SCIDmice. After 7 day
the combination via i.p. injection three times a week. Tumor volumes were measu
fitted to exponential growth models to derive tumor-doubling time (DT). Kaplan-
(D) Proteins were detected by immunoblotting, three tumors per group.
(E) Tumor lysates were used to quantitate AOs, five tumors per group (mean ± S
(F) Tumor lysates were used to seed Ab1-42 peptides, five tumors per group (me
(G) Tumor sections were stained with CR, five tumors per group. Ten random fi
rescence in each field was quantitated using ImageJ and normalized against tot
(H) Following CR staining, tumor sections were visualized under polarized light m
(I) Following staining with AF-specific antibodies (OC), sections of tumors recei
50 mm.
(J) A2058 cells (13 106) stably expressing firefly luciferase transgene were intrave
as described in (B) for 6 weeks. Body weights were monitored weekly (mean ± S
(K) Detection of metastases by in vivo bioluminescence imaging.
(L) Representative micrographs illustrate metastatic melanomas in the lung, skele
bone; A, adipose tissue; OF, ovarian follicle. Scale bar represents 500 mm.
(M) Combined MEK and proteasome inhibition prevents experimental melanoma
See also Figure S6 and Table S2.CR and ThT Staining of Tumor Sections
Following deparaffinization and rehydration, tumor sections were stained with
0.5%CR in PBS at RT for 20min followed by differentiation in alkaline solutions
(0.01%NaOH, 50% alcohol). Nuclei were stained with either Hoechst 33342 or
hematoxylin. Fluorescence was visualized using a Leica TCS SP5 confocal mi-
croscope and the birefringence visualized using a Leica DM5000B upright mi-
croscope equipped with polarized light filters. For ThT staining, sections were
stained with 0.2% ThT in PBS at RT for 10 min, rinsed in 1% acetic acid for
2 min, and washed with ddH2O three times. Nuclei were stained with SYTO
62 (Life Technologies).
Melanoma Xenograft Models
A2058 cells were subcutaneously (s.c.) injected into the left flanks of 9-week-
old female NOD.CB17-Prkdc <scid>/J (NOD/SCID) mice (The Jackson Labo-
ratory). For CR treatment, mice were intraperitoneally (i.p.) injectedwith PBS or
CR 1 day prior to combined AZD6244 and Bortezomib treatments. Tumor vol-
umes were calculated following the formula 4/3pR3. For experimental metas-
tasis, engineered A2058 cells were transplanted into 10-week-old female
NOD/SCIDmice via tail vein injections. All mouse experiments were performed
under a protocol approved by The Jackson Laboratory Animal Care and Use
Committee.
Statistical Methods
All statistical analyses were performed using Prism 6.0 (GraphPad software).
Statistical significance: *p < 0.05; **p < 0.01; ***p < 0.001.
See also the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two tables and can be foundwith this article online at http://dx.doi.
org/10.1016/j.cell.2015.01.028.
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Figure 7. Amyloidogenesis Suppresses Tumor Growth
(A) Sections of melanomas receiving combined treatment were stained with cleaved caspase 3 antibodies followed by CR staining. Arrowheads and arrows
indicate condensed and fragmented nuclei, respectively. Scale bar represents 50 mm.
(B) A2058 cells (1 3 106) were s.c. injected into NOD/SCID mice. After 7 days, mice were treated with 1 mg/30 g CR via i.p. injection 1 day prior to combined
treatment. Tumor volumes were measured weekly (mean ± SD, ANOVA).
(C) Lysates of CR-treated tumors exhibited absorbance at 498 nm, three tumors per group (mean ± SD, n = 3). Lysis buffer containing CR served as a positive
control.
(D) Kaplan-Meier survival curves were compared (Log-rank test).
(E and F) Both detergent-soluble and detergent-insoluble fractions of tumor lysates were used to quantitate amyloids, three tumors per group (mean ± SD, n = 3,
Student’s t test).
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